FDA Delays Mifepristone Review to March as 2023 Telehealth and Mail Rules Stay in Place
Updated
Updated · POLITICO · Oct 8
FDA Delays Mifepristone Review to March as 2023 Telehealth and Mail Rules Stay in Place
2 articles · Updated · POLITICO · Oct 8
Summary
March is the new target for the FDA’s mifepristone review, the agency told a Louisiana judge in a five-page filing, saying any changes to access will come only after that timeline.
The review is reexamining the Biden administration’s 2023 decision to allow telehealth prescribing and mailing of the abortion pill, while analyzing internal and external data on patient complications.
More than two-thirds of U.S. abortions use mifepristone in a two-drug regimen, and telemedicine access has been a major driver of rising abortion numbers since Roe v. Wade was overturned in 2022.
More than 100 peer-reviewed studies since the drug’s 2000 approval have found it safe and effective, but GOP states and anti-abortion groups are still pressing for tighter restrictions as the Trump administration asks courts to wait.
What hidden details in the FDA's private review could permanently alter how millions access telehealth medications?
How might a single court ruling on this medication disrupt future medical research for fibroids and endometriosis nationwide?
The Future of Medication Abortion: How Legal Battles Over Mifepristone Threaten Access for 65% of U.S. Abortions
Overview
The FDA’s October 7, 2026 update on mifepristone comes amid intense political and legal pressure, with a federal judge’s deadline driving the agency’s ongoing safety review. Political shifts and anti-abortion advocacy accelerated the review, while the Trump administration delayed final decisions until after the midterms. If the Fifth Circuit rules for Louisiana, nationwide telehealth and mail-order access to mifepristone would halt, forcing patients to travel for care and creating major barriers, especially for rural and vulnerable populations. This legal battle threatens not only abortion access but also the FDA’s authority, as states and courts challenge science-based drug approvals, risking broader impacts on healthcare and drug development.